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Background
The direct renin inhibitor (DRI) aliskiren has been pro-
posed as an alternative to angiotensin II-converting 
enzyme inhibitor (ACEi) or angiotensin II receptor blocker 
(ARB) therapy in the management of cardiovascular mor-
bidity and mortality in diabetes mellitus,1 with similar 
antihypertensive efficacy to ACEi or ARB.2–5 However, 
large clinical trials evaluating cardiovascular clinical end-
points have failed to demonstrate non-inferiority with 
aliskiren compared to ACEi or ARB treatment and have 
identified potential safety concerns in diabetic patients 
when used in addition with ACEi or ARB.6,7
The aim of this meta-analysis is to investigate the effi-
cacy and safety of aliskiren use in addition with back-
ground medical therapy in patients with diabetes and high 
cardiovascular risk or established cardiovascular disease.
Methods
This article is written in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analysis guidelines.8 No published protocol for this sys-
tematic review and meta-analysis exists.
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Abstract
Background: Aliskiren was shown to increase adverse events in patients with diabetes and concomitant renin–
angiotensin blockade. We aim to investigate the efficacy and safety of aliskiren in patients with diabetes and increased 
cardiovascular risk or established cardiovascular disease.
Methods: MEDLINE and Embase were searched for prospective studies comparing addition of aliskiren to standard 
medical therapy in patients with diabetes and cardiovascular disease, or ⩾1 additional cardiovascular risk factor 
(hypertension, abnormal lipid profile, microalbuminuria/proteinuria, chronic kidney disease). Relative risk for efficacy 
(all-cause mortality, combined cardiovascular mortality and hospitalisation) and safety (hyperkalaemia, hypotension, renal 
impairment) outcomes was calculated.
Results: Of 2151 studies identified in the search, seven studies enrolling 13,395 patients were included. Aliskiren 
had no effect on all-cause mortality (relative risk: 1.05, 95% confidence interval: 0.90 to 1.24, p = 0.53), or combined 
cardiovascular mortality or heart failure hospitalisation (relative risk: 1.07, 95% confidence interval: 0.81 to 1.40, p = 0.64). 
Patients receiving aliskiren had a greater risk of developing hyperkalaemia (relative risk: 1.32, 95% confidence interval: 
1.14 to 1.53, p = 0.0003) and renal impairment (relative risk: 1.15, 95% confidence interval: 1.02 to 1.30, p = 0.03), but 
not hypotension.
Conclusion: Patients with diabetes and cardiovascular disease or cardiovascular risk do not benefit from the addition of 
aliskiren to standard medical therapy. Detrimental safety profile in pooled analysis supports current warnings.
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Data sources and search strategy
A systematic search of MEDLINE and Embase databases 
was performed on 3 October 2016 using the terms 
Aliskiren, Tekturna, Rasilez, SPP100, renin inhibitor and 
Diabetes. Results were filtered from 1 January 2000. The 
reference lists of included studies and reviews were 
hand-searched for additional articles. The Novartis clini-
cal trials database9 was searched for additional data of 
completed trials.
Study selection criteria
We included prospective studies that enrolled patients 
with diabetes and established or history of cardiovascular 
disease, or at least one cardiovascular risk factor (study-
defined hypertension, raised low-density lipoprotein, 
reduced high-density lipoprotein, microalbuminuria, pro-
teinuria or chronic kidney disease). Studies were required to 
compare aliskiren dual therapy with ACEi or ARB, with 
either placebo or ACEi/ARB monotherapy. Included studies 
were required to report all-cause mortality stratified by dia-
betes status. To assess the long-term efficacy, studies with 
follow-up (mean/median) of ⩾6 months were included.
Data extraction and quality assessment
Study selection, data extraction and quality assessment 
were performed independently by two authors (S.L.Z., 
A.R.). After removal of duplicates, title and abstracts were 
screened for relevance, with full texts of remaining results 
assessed for inclusion based on pre-determined inclusion 
criteria. Inclusion required agreement between reviewers 
(S.L.Z., A.R.). The data extracted from each report 
included general study characteristics (study name, pri-
mary investigator, year of publication, median or mean 
duration of follow-up, inclusion and exclusion criteria), 
participant characteristics (number, age, gender, cardio-
vascular co-morbidities – hypertension, heart failure, pre-
vious myocardial infarction, concomitant use of ACEi 
and/or ARB), outcome data [hazard risk, risk or odds ratios 
with 95% confidence intervals (CIs), and absolute num-
bers] and adverse events (study-defined hyperkalaemia, 
hypotension and renal impairment).
Study corresponding authors were contacted for addi-
tional information where required.
The Cochrane Collaboration risk of bias tool was used 
to assess risk of bias. All studies had low risk of bias, with 
no impact on data synthesis.
Statistical analysis
Primary efficacy outcome was all-cause mortality. 
Secondary efficacy outcome was combined cardiovascular 
mortality and heart failure hospitalisation. Primary safety 
outcomes were hyperkalaemia, hypotension and renal 
impairment. Relative risk (RR) was calculated from raw 
published study data. Review Manager 5.3 was used for 
statistical analysis.10 Mantel–Haenszel method was used to 
calculate estimates, CIs and p-values. Random-effects 
models were used to summarise data. p-values for hetero-
geneity were calculated using chi-square test.
Results
Study selection and baseline characteristics
The search identified 2150 articles. Seven were included 
for meta-analysis (Figure 1 – study flow chart), enrolling 
13,395 patients with diabetes (Table 1 – baseline charac-
teristics). The participants were followed up for a mean of 
24.8 months, totalling 27,683 patient-years follow-up. 
There were five randomised controlled trials (RCTs)11–16 
and one observational study.17 The largest trials were 
Aliskiren Trial in Type 2 Diabetes Using Cardiorenal 
Endpoints (ALTITUDE); (8552 participants),12 the 3A 
registry (1936)17 and Aliskiren Trial to Minimize 
Outcomes in Patients with Heart Failure (ATMOSPHERE); 
(1317).16 Two RCTs enrolled participants with diabetes 
and high cardiovascular risk (Aliskiren in the Evaluation 
of Proteinuria in Diabetes (AVOID), ALTITUDE, 
n = 9151), four RCTs enrolled participants with diabetes 
and established cardiovascular disease [Aliskiren Study in 
Post-MI Patients to Reduce Remodelling (ASPIRE), 
Aliskiren Trial on Acute Heart Failure Outcomes 
(ASTRONAUT), Aliskiren Quantitative Atherosclerosis 
Regression Intravascular Ultrasound Study (AQUARIUS), 
ATMOSPHERE, n = 2935] and one observational study 
enrolled participants with hypertension (3A Registry, 
n = 3038).
Effect of aliskiren on outcomes
Aliskiren was associated with the same risk of death 
compared with controls (RR: 1.05, 95% CI: 0.90 to 1.24, 
p = 0.53, I2 = 27%; Figure 2(a)). There was no difference in 
combined cardiovascular mortality and heart failure hospi-
talisation between aliskiren and controls (RR: 1.07, 95% 
CI: 0.81 to 1.40, p = 0.64, I2 = 78%; Figure 2(b)).
Among 2308 patients with established cardiovascular 
disease, aliskiren was not associated with reductions in all-
cause mortality (RR: 1.08, 95% CI: 0.76 to 1.54, p = 0.66) 
or combined cardiovascular mortality and heart failure 
hospitalisation (RR: 0.96, 95% CI: 0.83 to 1.09, p = 0.51) 
compared with controls (Supplementary Figure 1).
Effect of aliskiren on blood pressure and 
urinary albumin-to-creatinine ratio
Three trials reported change in blood pressure between 
aliskiren and control groups, all of which favoured the 
addition of aliskiren. Two trials reported on change in 
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urinary albumin-to-creatinine ratio, again both in favour of 
aliskiren (Table 2).
Adverse events
Rates of hyperkalaemia, renal impairment and hypoten-
sion were reported in five, five and four RCTs, respec-
tively. Patients receiving aliskiren had greater risk of 
developing hyperkalaemia [RR: 1.32, 95% CI: 1.14 to 
1.53, p = 0.0003, absolute risk reduction (ARR): 6%] and 
renal impairment (pooled RR: 1.15, 95% CI: 1.02 to 1.30, 
p = 0.03, ARR 1%) compared with controls (Figure 3(a) 
and (b)). There was no increase in risk of developing hypo-
tension in patients with diabetes given aliskiren (RR: 1.22, 
95% CI: 0.80 to 1.85, p = 0.035; Figure 3(c)). Study with-
drawal in RCTs due to adverse events was only reported in 
two trials (Table 2).
Study quality and risk of publication bias
All RCTs had low overall risk of bias, and funnel plot 
showed little evidence of publication bias (Supplementary 
Figures 2 and 3).
Discussion
The findings of this meta-analysis demonstrate that 
aliskiren has no effect on all-cause mortality or combined 
cardiovascular mortality and heart failure hospitalisation 
in patients with diabetes and cardiovascular risk or estab-
lished disease. Pooled analysis demonstrated an increased 
risk of hyperkalaemia and renal impairment with aliskiren.
This meta-analysis is the first to examine the efficacy 
and safety of aliskiren in trial patients with high-risk 
diabetes, a group where renin–angiotensin system (RAS) 
inhibition reduces cardiovascular outcomes.18 We compare 
Figure 1. Study flow chart.
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use of aliskiren with placebo or single ACEi/ARB in 
patients with diabetes. There were high rates of concomi-
tant ACEi or ARB use in trial participants (85–100% in 
individual trials, and 99.1% in the pooled trial population). 
Our findings can therefore be cautiously interpreted as an 
increased risk with dual RAS blockade using aliskiren for 
hyperkalaemia and renal impairment of 32% (population 
risk ranges: 14%–53%) and 15% (population risk ranges: 
2%–30%) respectively. This supports the US Food and 
Drug Administration and European Medicines Agency 
safety announcements warning against the use of aliskiren 
in combination with ACEi or ARB in patients with 
diabetes.
Dual RAS blockade in diabetic patients with high 
cardiovascular risk does not improve outcomes and is asso-
ciated with increased adverse events,19 a conclusion that is 
extended to the use of aliskiren and supported by this meta-
analysis. It remains to be seen whether aliskiren as mono-
therapy is of benefit, and whether it serves as an alternative 
in patients intolerant of ACEi and ARB. In meta-analysis of 
Figure 2. Forest plot of (a) all-cause mortality and (b) combined cardiovascular mortality and hospitalisation for heart failure.
Table 2. Changes in urinary albumin-to-creatinine ratio, blood pressure (difference in change between aliskiren and control group) 
and discontinuations due to adverse events in randomised controlled trials.
Trial Baseline ACR 
(aliskiren 
group)
% change in 
urine ACR
Baseline sitting 
blood pressure 
(aliskiren group)
Change in 
blood pressure 
(aliskiren − control)
Discontinuations 
due to adverse event 
– aliskiren group
Discontinuations 
due to adverse event 
– control group
AVOID 513 −18% 135/78 mmHg −2/1 mmHg 17 (5.6%) 19 (6.4%)
ALTITUDE 206 −16% 137/74 mmHg −1.9/1 mmHg 563 (13.2%) 437 (10.2%)
ASPIRE NR NR NR NR NR NR
ASTRONAUT NR NR NR NR NR NR
AQUARIUS NR NR 132/77 mmHg −3/0.6 mmHg NR NR
ATMOSPHERE NR NR 127 mmHg (SBP) NR NR NR
ALTITUDE: Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints; ATMOSPHERE: Aliskiren Trial to Minimize Outcomes in Patients with 
Heart Failure; ASPIRE: Aliskiren Study in Post-MI Patients to Reduce Remodelling; ASTRONAUT: Aliskiren Trial on Acute Heart Failure Outcomes; 
AQUARIUS: Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study; ACR: albumin-to-creatinine ratio; NR: not reported; 
SBP: systolic blood pressure.
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blood pressure reduction, aliskiren showed superior 
efficacy over ACEi and equivalence with ARB.20 Current 
evidence suggests that in diabetic patients without specific 
indications for RAS blockade, RAS blockade was not 
superior in improving cardiovascular outcomes compared 
with alternative blood pressure–reducing therapies.21
Study limitations
Limitations of this study include those inherent in meta-
analyses, which are driven primarily by availability and 
accessibility of data. Adverse events were trial defined, 
and so conclusions on increased risk of these are not 
with universal definitions. We are unable to comment on 
whether there may be benefit of aliskiren over other RAS 
blockers stratified by cardiovascular diagnosis (e.g. heart 
failure, post-myocardial infarction or hypertension) due to 
inability to extract relevant data. While subgroup data 
from ATMOSPHERE suggested benefit of aliskiren in 
patients with diabetes and heart failure (HR: 0.87, Upper 
confidence interval (UCI): 1.09), pooled data from the 
three studies that enrolled heart failure patients showed no 
effect (data not presented).
In conclusion, in patients with diabetes and cardiovas-
cular disease or raised cardiovascular risk, the addition of 
aliskiren has no effect on all-cause mortality and combined 
cardiovascular mortality or heart failure hospitalisation 
compared with control treatment. There is an increased 
risk of hyperkalaemia and renal impairment with the use of 
aliskiren in addition to baseline ACEi and ARB therapy. 
This study supports current warnings against aliskiren use 
in patients with diabetes.
Figure 3. Forest plot of adverse events: (a) hyperkalaemia, (b) renal impairment and (c) hypotension.
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